Synergy San Diego | Lemon Grove, CA

Research site

(Unclaimed)

Location

7922 Palm Street, Lemon Grove, California, United States of America

Site insights

Top conditions

Top treatments

SEP-363856

Cariprazine

KarXT

Rapastinel

Pimavanserin

RO6889450

Ralmitaront

BHV-7000

BI 425809

LB-102

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 50 total trials

A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder

Major depressive disorder (MDD; depression) is a mood disorder that causes a continued feeling of sadness and loss of interest. It is a common and se...

Enrolling

Major Depressive Disorder

Drug: Icalcaprant

Drug: Placebo for Icalcaprant

A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia

Evaluate the efficacy and safety of Ulotaront (SEP-363856) in acutely psychotic subjects with schizophrenia

Enrolling

Schizophrenia

Drug: SEP-363856

Other: Placebo

Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE. (Illuminate1)

Phase II study for patients with Bipolar 1 Disorder experiencing major depressive episode. Patient eligible for enrollment will be randomized (like f...

Enrolling

Bipolar I Disorder

Other: Placebo

Drug: LB-102

Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder

Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately t...

Enrolling

Generalized Anxiety Disorder (GAD)

Drug: Antidepressant Therapy (ADT)

Drug: ABBV-932

Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder

Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population in the United States. The purpose of this study is t...

Enrolling

Bipolar I or II Disorder

Drug: ABBV-932

Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia (NOVA2)

This is a Phase 3, randomized, double blind, placebo controlled, fixed dose, study designed to evaluate the efficacy, safety, tolerability, and of LB...

Enrolling

Schizophrenia

Other: Placebo

Drug: LB-102 (100 mg tablet)